CDMOs & Contract Manufacturers
Contract development and manufacturing organizations — running GMP manufacturing, commissioning & qualification, and validation on behalf of sponsors.
What this page does not claim
A sector is an organization’s role in the value chain, not a legal category. SPEQ maps the disciplines and standards that role typically operates under; it does not determine which apply to your organization, and a count of decoded standards measures SPEQ’s coverage.
WHAT THIS SECTOR DOES
Contract development and manufacturing organizations (CDMOs) — and CMOs focused purely on manufacturing — make drug substance and drug product on behalf of the companies that own the marketing authorization. They run GMP manufacturing, commissioning & qualification, and validation for products they did not design, often across many clients and modalities in the same facility. A large and growing share of the world’s medicines is made this way.
REGULATORY LANDSCAPE
A CDMO operates the same GMP the sponsor would: FDA 21 CFR 210/211 for finished product and ICH Q7 for APIs, EU GMP (including Annex 1 for sterile), and ICH Q9/Q10 for risk and the quality system. The defining regulation is EU GMP Chapter 7 (Outsourced Activities), which governs the contract-giver / contract-acceptor relationship, and its FDA analogue — the agency’s guidance on contract manufacturing arrangements for drugs.
THE OVERSIGHT MODEL
Quality is shared but accountability is not transferable: under EU GMP Chapter 7 the sponsor (contract giver) remains ultimately responsible for the product and must audit and approve the CDMO, while the CDMO (contract acceptor) is responsible for the work it performs. A written Quality Agreement defines the split — who releases, who investigates, who owns change control — and is the first document an inspector asks for.
WHAT QUALITY MEANS HERE
Technology transfer
Receiving a process from the sponsor and proving it is understood, capable, and validated at the new site — the make-or-break activity for every new product a CDMO takes on.
Multi-client segregation & changeover
Cleaning validation, campaign changeover, and cross-contamination control (HBEL-based limits) that keep one client’s product from contaminating another’s in shared facilities.
Commissioning & qualification
Risk-based C&Q of facilities, utilities, and equipment (ASTM E2500 / ISPE Vol. 5), and the validated state that every client’s product depends on.
The Quality Agreement
A living contract that assigns every GMP responsibility between contract giver and acceptor — the backbone of a defensible outsourced-manufacturing relationship.
STANDARDS SPEQ DECODES · 180
Open the full library →WHERE QUALITY FAILS
- Quality Agreements that are missing, stale, or silent on who owns key decisions
- Cross-contamination or mix-ups from weak changeover and segregation controls
- Technology transfers that skip process understanding and fail at scale
- Client change controls and deviations that fall between the two quality systems
KEY REGULATORY BODIES
Derived from the 180 standards SPEQ decodes for this sector.
GXP DISCIPLINES IN THIS SECTOR
CDMOs & Contract Manufacturers: frequently asked questions
Reference answers on what a cdmos & contract manufacturers does, what governs it, and who is accountable for quality.
What is a CDMO?
A contract development and manufacturing organization makes drug substance or drug product on behalf of the company that owns the marketing authorization. It runs GMP manufacturing, commissioning and qualification, and validation for products it did not design — often for many clients across shared facilities. A CMO does the manufacturing without the development services.
Which regulations govern a CDMO?
A CDMO runs the same GMP the sponsor would: FDA 21 CFR 210/211 for finished product, ICH Q7 for APIs, EU GMP (including Annex 1 for sterile), and ICH Q9/Q10 for risk and the quality system. The defining rule is EU GMP Chapter 7, Outsourced Activities, which governs the contract-giver / contract-acceptor relationship.
Who is accountable for quality in an outsourced-manufacturing arrangement?
Accountability is not transferable. Under EU GMP Chapter 7 the sponsor, as contract giver, remains ultimately responsible for the product and must audit and approve the CDMO; the CDMO, as contract acceptor, is responsible for the work it performs. A written Quality Agreement defines the split — who releases, who investigates, who owns change control.